By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Medco Health Solutions will offer patients diagnosed with chronic myeloid leukemia a companion diagnostic test to assess their response to tyrosine kinase inhibitor, or TKI, therapy under an agreement with MolecularMD announced today.

MolecularMD's qRT-PCR BCR-ABL assay will be used to help physicians make treatment decisions and to monitor patients on TKI therapy, under the terms of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.